Christian Fesl
Overview
Explore the profile of Christian Fesl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1062
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El Kababji S, Mitsakakis N, Jonker E, Beltran-Bless A, Pond G, Vandermeer L, et al.
J Med Internet Res
. 2025 Mar;
27:e66821.
PMID: 40053790
Background: Insufficient patient accrual is a major challenge in clinical trials and can result in underpowered studies, as well as exposing study participants to toxicity and additional costs, with limited...
2.
Wimmer K, Hlauschek D, Balic M, Pfeiler G, Greil R, Singer C, et al.
Breast
. 2025 Feb;
80:104415.
PMID: 39985843
Background: The Clinical Treatment Score post-5 years (CTS5) is a clinicopathological tool designed to estimate late distant recurrence (LDR) in hormone receptor-positive (HR+) breast cancer patients after 5 years of...
3.
Singer C, Jahn S, Hlauschek D, Heber U, Mang-Manger C, Egle D, et al.
Cancer Commun (Lond)
. 2025 Jan;
PMID: 39757921
No abstract available.
4.
Knobl V, Maier L, Grasl S, Kratzer C, Winkler F, Eder V, et al.
J Transl Med
. 2024 Oct;
22(1):913.
PMID: 39380101
Background: Monocytes comprise subsets of classical, intermediate and non-classical monocytes with distinct anti- or pro-tumor effects in breast cancer (BC). They are modulated by estrogen, and can contribute to BC...
5.
Nader-Marta G, Singer C, Hlauschek D, DeMichele A, Tarantino P, de Azambuja E, et al.
Breast Cancer Res
. 2024 Oct;
26(1):140.
PMID: 39375745
Background: Bidirectional crosstalk between HER2 and estrogen receptor (ER) pathways may influence outcomes and the efficacy of endocrine therapy (ET). Low HER2 expression levels (HER2-low) have emerged as a predictive...
6.
7.
Wimmer K, Hlauschek D, Balic M, Pfeiler G, Greil R, Singer C, et al.
Breast Cancer Res Treat
. 2024 May;
206(2):441.
PMID: 38704775
No abstract available.
8.
Gnant M, Frantal S, Pfeiler G, Steger G, Egle D, Greil R, et al.
NEJM Evid
. 2024 Feb;
1(12):EVIDoa2200162.
PMID: 38319865
BACKGROUND: Adjuvant aromatase inhibitors increase osteoporosis and fractures in patients with hormone receptor–positive breast cancer. We have previously reported outcomes of the ABCSG-18 (study 18 from the Austrian Breast &...
9.
Wimmer K, Hlauschek D, Balic M, Pfeiler G, Greil R, Singer C, et al.
Breast Cancer Res Treat
. 2024 Jan;
205(2):227-239.
PMID: 38273214
Purpose: The Clinical Treatment Score post-5 years (CTS5) is an easy-to-use tool estimating the late distant recurrence (LDR) risk in patients with hormone receptor-positive breast cancer after 5 years of...
10.
Pfeiler G, Hlauschek D, Mayer E, Deutschmann C, Kacerovsky-Strobl S, Martin M, et al.
J Clin Oncol
. 2023 Aug;
41(33):5118-5130.
PMID: 37556775
Purpose: BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of BMI or weight. This preplanned analysis of...